| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 4.21 | 95.0% |
| Total Income | 4.21 | 95.0% |
| Expenditure | 54.24 | 32.6% |
| PBT | -44.45 | 193.2% |
| Net Profit | -44.50 | 194.9% |
| OPM | — | |
| NPM | — | |
| EPS | — |
Monte Rosa Therapeutics Reports Q1 2026 Financial Results and Business Updates
07 May 2026 · 7 May, 4:38 pm
Summary
Monte Rosa Therapeutics reported its first quarter 2026 financial results, with a net loss of $44.5 million compared to a net income of $46.9 million in the same quarter of the previous year. Collaboration revenue decreased to $4.2 million from $84.9 million year-over-year, while R&D expenses increased to $44.1 million from $32.2 million. The company's cash position remains strong at $671 million, expected to fund operations into 2029. Monte Rosa is advancing multiple programs through the clinic, with Phase 2 trial initiations expected for several programs.
Key Highlights
- 1
Monte Rosa Therapeutics reported cash, cash equivalents, restricted cash, and marketable securities of $671 million as of March 31, 2026, expected to support operations into 2029.
- 2
The company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026.
- 3
Collaboration revenue for the first quarter of 2026 was $4.2 million, compared to $84.9 million for the first quarter of 2025.
- 4
Research and Development expenses for the first quarter of 2026 were $44.1 million, compared to $32.2 million for the first quarter of 2025.
- 5
Net loss for the first quarter of 2026 was $44.5 million, compared to $46.9 million net income for the first quarter of 2025.
- 6
The company plans to initiate a Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026.
- 7
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk.
Management Comments
Markus Warmuth
“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations. Building on interim clinical data for our NEK7-directed MGD MRT-8102 demonstrating rapid, deep, and durable reductions in systemic inflammation, we expect to read out the GFORCE-1 study in subjects with elevated cardiovascular disease (CVD) risk this year, and to initiate three Phase 2 studies, starting in H2 2026, in diseases driven by the NLRP3/IL-1/IL-6 pathway. We also expect our collaborator Novartis to initiate multiple Phase 2 studies of our VAV1-directed MGD MRT-6160 in immune-mediated diseases this year. In addition, our oncology programs are also progressing rapidly, in particular with a Phase 2 study initiation of MRT-2359 in metastatic castration-resistant prostate cancer (mCRPC) patients with androgen receptor (AR) mutations planned for Q3 2026, following the encouraging Phase 1/2 data we presented at ASCO GU.”
Informational and educational content only. Not investment advice.